Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedincellMDCLF +393.00%77 Cash-to-Debt is 1.54 as of Mar. 2026, which is 221% above its 10-year median of 0.48. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review. Among 1,403 Biotechnology companies, Medincell ranks worse than 71.35% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Medincell's cash to debt ratio for the quarter that ended in Mar. 2026 was 1.54.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Medincellcould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Medincell's Cash-to-Debt or its related term are showing as below:
MDCLF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12 Med: 0.48 Max: 1.54
Current: 1.54
During the past 11 years, Medincell's highest Cash to Debt Ratio was 1.54. The lowest was 0.12. And the median was 0.48.
MDCLF's Cash-to-Debt is ranked worse than 71.35% of 1403
companies
in the Biotechnology industry
Industry Median: 6.45
vs MDCLF: 1.54
Medincell (OTCPK:MDCLF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Medincell Cash-to-Debt Related Terms
Medincell Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Medincell's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MDCLF vs VRTX, REGN, ALNY: Cash-to-Debt Comparison
For the Biotechnology subindustry, Medincell's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Medincell's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medincell (MDCLF) has a Cash-to-Debt of 1.54 as of Mar. 2026. This is 221% above median its historical median of 0.48. Over the past decade, Medincell's Cash-to-Debt has ranged from 0.12 to 1.54. According to the industry distribution chart, Medincell ranks #1001 out of 1403 companies in the Biotechnology industry, placing it in the top 71.3%.
Is Medincell's Cash-to-Debt too high?
Medincell's current Cash-to-Debt of 1.54 is 221% above median its 10-year median of 0.48. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 1.54. The Biotechnology industry median Cash-to-Debt is 6.45. Medincell's value of 1.54 is 76.1% below this industry median. Based on the distribution chart, Medincell ranks #1001 out of 1403 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #1001 out of 1403 companies for Cash-to-Debt. This places Medincell in the lower half of its industry. The industry median Cash-to-Debt is 6.45. Medincell's value of 1.54 is 76.1% below this benchmark. Historically, Medincell's own Cash-to-Debt has ranged from 0.12 to 1.54 over the past decade. While the company's 10-year median is 0.48 vs. the industry median of 6.45, Medincell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.45, based on 1,403 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medincell's current Cash-to-Debt of 1.54 is 76.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current Cash-to-Debt is 1.54, which is 221% above median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Cash-to-Debt of 1.54. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Cash-to-Debt is 1.54, which is 221% above median its 10-year median of 0.48 and 76.1% below the Biotechnology industry median of 6.45. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Medincell (MDCLF), the current Cash-to-Debt is 1.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.
Key valuation signals for MDCLF:
Cash-to-Debt: 1.54 (221% above median its 10-year median of 0.48)
GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
Industry Position: 76.1% below the Biotechnology median (#1001 of 1403)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
